David Schnell October 17, 2022 NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration David Schnell October 17, 2022
David Schnell September 13, 2022 NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination Treatment for Metastatic Pancreatic Cancer at AACR David Schnell September 13, 2022
David Schnell September 6, 2022 Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy David Schnell September 6, 2022
David Schnell August 15, 2022 NGM Bio To Present Findings from Ongoing Phase 1a Dose Escalation Trial in Patients with Advanced Solid Tumors at ESMO and Phase 1b Trial of NGM120 in Advanced Pancreatic Cancer at AACR David Schnell August 15, 2022
David Schnell March 31, 2022 NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors David Schnell March 31, 2022
David Schnell February 11, 2022 Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy David Schnell February 11, 2022
David Schnell February 7, 2022 NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration David Schnell February 7, 2022
David Schnell December 6, 2021 Dec 6, 2021 - NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® David Schnell December 6, 2021
David Schnell September 16, 2021 Sept 16, 2021 - NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at ESMO David Schnell September 16, 2021
David Schnell August 23, 2021 August 23, 2021 - NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research David Schnell August 23, 2021
David Schnell July 22, 2021 July 22, 2021 - NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration David Schnell July 22, 2021
David Schnell July 7, 2021 July 7, 2021 - NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors David Schnell July 7, 2021
David Schnell July 1, 2021 July 1, 2021 - NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases David Schnell July 1, 2021
David Schnell May 24, 2021 May 24, 2021 - NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH David Schnell May 24, 2021
David Schnell March 2, 2021 March 2, 2021 - NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer David Schnell March 2, 2021
David Schnell February 9, 2021 Feb 9, 2021 - NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition David Schnell February 9, 2021
David Schnell January 12, 2021 Jan 12, 2021 - NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology David Schnell January 12, 2021
David Schnell January 6, 2021 Jan 5, 2021 - NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock David Schnell January 6, 2021
David Schnell December 9, 2020 Dec 9, 2020 - NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors David Schnell December 9, 2020
David Schnell November 13, 2020 Nov 13, 2020 - NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 David Schnell November 13, 2020
